90Y Clivatuzumab Tetraxetan

N/A

Report date: 2025/09/08 17:55:44

Base Information

Drug Name90Y Clivatuzumab Tetraxetan

Drug Alias NamePan-CideYttrium-90 labelled monoclonal antibody PAM4Humanised monoclonal antibody PAM4 Y-90Yttrium-(90Y) clivatuzumab tetraxetanYttrium-90 clivatuzumab tetraxetan +[17]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionIonising radiation emittersAnti-MUC1

TargetsMucin-1

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[8]

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGilead Sciences Inc

Active IndicationsN/A

Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A